These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 23152680)

  • 1. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
    Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: an administrative claims data analysis.
    Abudagga A; Sun SX; Tan H; Solem CT
    Int J Chron Obstruct Pulmon Dis; 2013; 8():175-85. PubMed ID: 23589684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
    Moll K; Sun SX; Ellis JJ; Howe A; Amin A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
    Schwab P; Dhamane AD; Hopson SD; Moretz C; Annavarapu S; Burslem K; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2017; 12():735-744. PubMed ID: 28260880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population.
    Sethi S; Make BJ; Robinson SB; Kumar S; Pollack M; Moretz C; Dreyfus J; Xi A; Powell D; Feigler N
    Int J Chron Obstruct Pulmon Dis; 2022; 17():593-608. PubMed ID: 35342290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COPD exacerbation frequency and its association with health care resource utilization and costs.
    Dhamane AD; Moretz C; Zhou Y; Burslem K; Saverno K; Jain G; Renda A; Kaila S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2609-18. PubMed ID: 26664109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare utilization and costs among chronic bronchitis patients treated with maintenance medications from a US managed care population.
    AbuDagga A; Sun SX; Tan H; Solem CT
    J Med Econ; 2013; 16(3):421-9. PubMed ID: 23336296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of the Aerobika* oscillating positive expiratory pressure device in the management of COPD exacerbations.
    Khoudigian-Sinani S; Kowal S; Suggett JA; Coppolo DP
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3065-3073. PubMed ID: 29089755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
    Tkacz J; Evans KA; Touchette DR; Portillo E; Strange C; Staresinic A; Feigler N; Patel S; Pollack M
    Int J Chron Obstruct Pulmon Dis; 2022; 17():329-342. PubMed ID: 35177901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data.
    Kim J; Rhee CK; Yoo KH; Kim YS; Lee SW; Park YB; Lee JH; Oh Y; Lee SD; Kim Y; Kim K; Yoon H
    Int J Chron Obstruct Pulmon Dis; 2013; 8():561-8. PubMed ID: 24277985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COPD management costs according to the frequency of COPD exacerbations in UK primary care.
    Punekar YS; Shukla A; Müllerova H
    Int J Chron Obstruct Pulmon Dis; 2014; 9():65-73. PubMed ID: 24426781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
    Yu AP; Yang H; Wu EQ; Setyawan J; Mocarski M; Blum S
    J Med Econ; 2011; 14(3):315-23. PubMed ID: 21500975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External Validation of a COPD Risk Measure in a Commercial and Medicare Population: The COPD Treatment Ratio.
    Stanford RH; Lau MS; Li Y; Stemkowski S
    J Manag Care Spec Pharm; 2019 Jan; 25(1):58-69. PubMed ID: 30589629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.
    Stanford RH; Nag A; Mapel DW; Lee TA; Rosiello R; Vekeman F; Gauthier-Loiselle M; Duh MS; Merrigan JF; Schatz M
    Ann Am Thorac Soc; 2016 Jul; 13(7):1067-75. PubMed ID: 27070274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.